



Charles M Beasley Jr
03/02/98 10:52 AM

To: Valerie Simmons/EMA/LLY@Lilly
cc: Man C Fung/AM/LLY@Lilly, Andrea Loew/EMA/LLY@Lilly, Edmundo Muniz/AM/LLY@Lilly, Cees Schep/EMA/LLY@Lilly, Anna Thornton/AM/LLY@Lilly, Gary D Tollefson/AM/LLY@Lilly
Subject: Re: OLANZAPINE AND HYPERGLYCAEMIA

We are also going back and looking at the course of the diabetics in clinical trials, over 100. Val, please give me a call to discuss further.

Gary, We should discuss.

Charles
Valerie Simmons



Valerie Simmons
03/02/98 09:17 AM

Sent by: Fiona Armour

To: Charles M Beasley Jr/AM/LLY@Lilly, Man C Fung/AM/LLY@Lilly
cc: Andrea Loew/EMA/LLY, Edmundo Muniz/AM/LLY@Lilly, Cees Schep/EMA/LLY, Anna Thornton/AM/LLY@Lilly
Subject: OLANZAPINE AND HYPERGLYCAEMIA

Dear Charles and Man,

I felt that you should be aware that the issue of olanzapine and hyperglycaemia has been raised in Germany, in addition to South Africa. In Germany, it has been pointed out that, in addition to the total number of case reports on the system, there are also a number of cases without underlying diabetic medical history or apparent risk factors e.g. cases with positive rechallenge (ES97071102A), no underlying history (US96123673A, US96124591A), with "normal" blood glucose values pre-treatment (e.g. US97072944A) or a well described German literature report (DE97105614A).

Under German law such cases, whilst extremely rare, nevertheless constitute "grounds for reasonable suspicion". I should therefore be extremely grateful if a full review of cumulative data could be included in the next olanzapine PSUR to show that we are continuing to keep this area under close scrutiny and to ensure that our current PI for the drug adequately reflects the body of evidence on our database.


Such a review is, of course, in response to the company's continued proactive surveillance policy in addition to meeting individual regulatory requirements.

I very much appreciate your support and assistance in this matter, as always.


ZY 1971 1471

Warm regards,
Val

ZY 1971 1472

 Valerie Simmons
03/03/98 06:31 AM

Sent by: Fiona Armour

To: Charles M Beasley Jr/AM/LLY@Lilly, Man C Fung/AM/LLY@Lilly
cc: Andrea Loew/EMA/LLY, Edmundo Muniz/AM/LLY@Lilly, Cees Schep/EMA/LLY, Anna
Thornton/AM/LLY@Lilly, Gary D Tollefson/AM/LLY@Lilly
Subject: Re: OLANZAPINE AND HYPERGLYCAEMIA 

Dear Charles and Man,

I just wanted to thank you both very much for responding so promptly to me on this issue. I am reassured to know that you are analysing the matter in some depth and look forward to hearing your recommendations. I also very much appreciate your consideration in taking the recent query from Germany into account.

If I can be of any assistance then please do not hesitate to contact me. In the meantime, once again, many thanks for your continued support - it is very much appreciated, I can assure you!

Warm regards,
Val

ZY 1971 1473

To: Charles M Beasley Jr/AM/LLY@Lilly
cc: Anna Thornton/AM/LLY@Lilly
Subject: Re: Resending of revised file on hyperglycemia

Charles,

Thank you for the kind words!


One thing that I am very much interested in is the time of onset of hyperglycemia relative to the initiation of olanzapine. I wonder if Mary Joe had captured that (it appeared that she did). It would be interesting to know what % of cases reported this event occurred within the first 2-3 months and what % after the first 2 or 3 months. I suspect that hyperglycemia occurred long after the initiation of olanzapine are less likely be drug-related (i.e. chance event) and therefore less likely be reversible upon discontinuation of the suspected drugs.

Anna,

You have sent me the hyperglycemia response document sent to Canada. It appears that Mary Joe had captured information on time of onset from spontaneous reports though she did not elaborate the findings in the response document. A plot of #reports by the time of onset of hyperglycemia would be informatiive.

Please provide me the information that Charles referred to below.

Charles M Beasley Jr on 09/09/99 07:40:49 PM

 Charles M Beasley Jr on 09/09/99 07:40:49 PM

To: Kenneth C Kwong/AM/LLY@Lilly
cc:
Subject: Re: Resending of revised file on hyperglycemia

This an EXCELLENT piece of work. I believe that Anna will be giving you a copy of the summary results from the database developed by Mary Joe Brandt. Although we included more COSTART terms (glycosuria, glucose tolerance test abnormal, etc.), you have captured most of the cases. MJB also broke patients down into 3 groups, depending on the nature of the presentation -- more Type I like or Type II like. You might just quickly look at this and make sure that I'm right that everything is basically in agreement.

Thanks for the hard work,
Charles

ZY 1971 1474